v3.7.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
NET REVENUE        
Clinical testing $ 59,791 $ 56,316 $ 116,482 $ 110,936
Pharma Services 6,299 6,813 11,285 11,896
Total Revenue 66,090 63,129 127,767 122,832
COST OF REVENUE 34,912 34,524 69,393 67,055
GROSS PROFIT 31,178 28,605 58,374 55,777
Operating expenses:        
General and administrative 22,675 18,779 43,476 36,785
Research and development 947 1,306 1,809 2,752
Sales and marketing 6,242 6,327 11,890 12,127
Total operating expenses 29,864 26,412 57,175 51,664
INCOME FROM OPERATIONS 1,314 2,193 1,199 4,113
Interest expense, net 1,411 1,448 2,775 3,040
Income (loss) before taxes (97) 745 (1,576) 1,073
Income tax (benefit) expense (54) 332 (879) 505
NET INCOME (LOSS) (43) 413 (697) 568
Deemed dividends on preferred stock 929 1,840 1,822 3,680
Amortization of preferred stock beneficial conversion feature 1,710 3,727 3,383 7,453
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (2,682) $ (5,154) $ (5,902) $ (10,565)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS        
Basic $ (0.03) $ (0.07) $ (0.07) $ (0.14)
Diluted $ (0.03) $ (0.07) $ (0.07) $ (0.14)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic 79,413 77,448 79,075 76,758
Diluted 79,413 77,448 79,075 76,758

Source